{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["62"],"submitter":["Brenner J"],"pubmed_abstract":["<h4>Background</h4>Anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis is a severe disease that primarily affects young people and can improve with adequate treatment. We aimed to refine the anti-NMDAR Encephalitis One-year functional Status (NEOS) score by developing NEOS2, an updated model using readily available data at the time of diagnosis. We assessed the predictive value of the NEOS2-score for (1) improvement following first-line treatment, (2) functional outcome at one-year follow-up, and (3) resumption of school or work within three years.<h4>Methods</h4>In this international (France, Germany, Japan, the Netherlands and Spain) cohort study in patients with a definite anti-NMDAR encephalitis diagnosis (according to the clinical criteria plus antibody testing in CSF), we pe"],"journal":["The Lancet regional health. Europe"],"pagination":["101562"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12757447"],"repository":["biostudies-literature"],"pubmed_title":["Development and validation of the NEOS2 score for prediction of long-term outcomes and improvement after first-line immunotherapy in patients with anti-NMDAR encephalitis: an international cohort study."],"pmcid":["PMC12757447"],"pubmed_authors":["Leypoldt F","GENERATE Study Group","Titulaer MJ","Angstwurm K","Honnorat J","Finke C","Heiden M","Lewerenz J","van Steenhoven RW","Millot M","Wandinger KP","Seifert-Held T","Volovici V","Ringelstein M","Kumpfel T","Wurdack K","Menge T","Tauber S","Geis C","Melzer N","Rauber S","Neuteboom RF","Eisenhut K","Roßling R","Bastiaansen AEM","Kraft A","Munoz-Lopetegi A","Muniz-Castrillo S","Berger R","Veenbergen S","Dalmau J","Pruss H","Brenner J","de Vries JM","de Bruijn MAAM","Ayzenberg I","Bertolini A","Rostasy K","Guasp M","Franken SC","Sillevis Smitt PAE","Picard G","Nagtzaam MMP","Bien C","Suhs KW","Klausewitz J","Martinez-Hernandez E","Crijnen YS","Vogrig A","Kerstens J","van den Berg R","Iizuka T","Ratuszny D","Thaler FS","Schreurs MWJ"],"additional_accession":[]},"is_claimable":false,"name":"Development and validation of the NEOS2 score for prediction of long-term outcomes and improvement after first-line immunotherapy in patients with anti-NMDAR encephalitis: an international cohort study.","description":"<h4>Background</h4>Anti-N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis is a severe disease that primarily affects young people and can improve with adequate treatment. We aimed to refine the anti-NMDAR Encephalitis One-year functional Status (NEOS) score by developing NEOS2, an updated model using readily available data at the time of diagnosis. We assessed the predictive value of the NEOS2-score for (1) improvement following first-line treatment, (2) functional outcome at one-year follow-up, and (3) resumption of school or work within three years.<h4>Methods</h4>In this international (France, Germany, Japan, the Netherlands and Spain) cohort study in patients with a definite anti-NMDAR encephalitis diagnosis (according to the clinical criteria plus antibody testing in CSF), we pe","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Mar","modification":"2026-06-06T10:44:18.076Z","creation":"2026-05-29T03:12:59.195Z"},"accession":"S-EPMC12757447","cross_references":{"pubmed":["41488792"],"doi":["10.1016/j.lanepe.2025.101562"]}}